Lee Biosolutions, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Lee Biosolutions, Inc. - overview
Established
1975
Location
Maryland Heights, MO, US
Primary Industry
Biotechnology
About
Lee Biosolutions, Inc. specializes in producing high-quality raw materials for the in vitro diagnostic market, offering essential products for life science research and diagnostic applications globally. Founded in 1975 and headquartered in Maryland Heights, US, Lee Biosolutions, Inc. focuses on the manufacturing of critical raw materials for diagnostics.
In November 2019, the company was acquired by Medix Biochemica Oy AB, which aims to enhance its growth within the US market. The acquisition facilitates broader access to Lee Biosolutions' products, enhancing Medix’s operational capabilities in the region. Lee Biosolutions operates under Medix Biochemica USA Inc. , manufacturing high purity antigens, proteins, enzymes, antibodies, biochemicals, and biological samples for the in vitro diagnostic market.
Their products support diverse applications in life science research and diagnostics, utilized by academic researchers, diagnostic manufacturers, and biopharmaceutical companies across North America, Europe, and Asia. They are ISO 13485 certified, ensuring compliance with regulatory standards for quality. Lee Biosolutions generates revenue through direct sales primarily to academic institutions, research organizations, and commercial diagnostics manufacturers. Their business model is B2B, focusing on bulk orders for high-quality products, including Myoglobin antigens and affinity-purified antibodies.
This structure allows for both standard and GMP-grade manufacturing services, fostering long-term partnerships critical for their market sustainability. Following its acquisition by Medix Biochemica Oy AB in November 2019, Lee Biosolutions aims to leverage this partnership to enhance its product offerings and expand into new markets. The company will focus on developing new diagnostic materials and increasing its reach in the US market, aligning with Medix’s strategic growth plans. The acquisition provides additional resources to support these initiatives, allowing for increased innovation and market penetration.
Current Investors
Oy Medix Biochemica Ab
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.leebio.com
Verticals
Manufacturing
Company Stage
Add-on
Total Amount Raised
Subscriber access only
Lee Biosolutions, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on | Completed | Lee Biosolutions, Inc. | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.